Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of malignant hypercalcaemia with clodronate.

Literature DB >> 3158326

Treatment of malignant hypercalcaemia with clodronate.

R C Percival, A D Paterson, A J Yates, D J Beard, D L Douglas, F E Neal, R G Russell, J A Kanis.

Abstract

We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1985 PMID： 3158326 PMCID： PMC1977044 DOI： 10.1038/bjc.1985.100

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

24 in total

1. Monitoring the treatment of Paget's disease with etidronate.

Authors: J A Kanis
Journal: Calcif Tissue Int Date: 1984-12 Impact factor: 4.333

2. Rehydration in the treatment of severe hypercalcaemia.

Authors: D J Hosking; A Cowley; C A Bucknall
Journal: Q J Med Date: 1981

3. Clodronate kinetics and bioavailability.

Authors: G J Yakatan; W J Poynor; R L Talbert; B F Floyd; C L Slough; R S Ampulski; J J Benedict
Journal: Clin Pharmacol Ther Date: 1982-03 Impact factor: 6.875

4. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity.

Authors: A F Stewart; A Vignery; A Silverglate; N D Ravin; V LiVolsi; A E Broadus; R Baron
Journal: J Clin Endocrinol Metab Date: 1982-08 Impact factor: 5.958

5. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

Authors: I Elomaa; C Blomqvist; P Gröhn; L Porkka; A L Kairento; K Selander; C Lamberg-Allardt; T Holmström
Journal: Lancet Date: 1983-01-22 Impact factor: 79.321

6. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors: F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal: Lancet Date: 1979-04-14 Impact factor: 79.321

7. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

Authors: D L Douglas; T Duckworth; R G Russell; J A Kanis; C J Preston; F E Preston; M A Prenton; J S Woodhead
Journal: Lancet Date: 1980-05-17 Impact factor: 79.321

8. Hypercalcaemia--a hospital survey.

Authors: R A Fisken; D A Heath; A M Bold
Journal: Q J Med Date: 1980

9. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.

Authors: T P Jacobs; E S Siris; J P Bilezikian; D C Baquiran; E Shane; R E Canfield
Journal: Ann Intern Med Date: 1981-03 Impact factor: 25.391

10. Parenteral diphosphonates for treating malignant hypercalcemia.

Authors: A Jung; C van Ouwenaller; A Chantraine; B Courvoisier
Journal: Cancer Date: 1981-10-15 Impact factor: 6.860

11 in total

Review 1. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors: H Fleisch
Journal: Drugs Date: 1991-12 Impact factor: 9.546

Treatment of malignant hypercalcaemia with clodronate.

1. Monitoring the treatment of Paget's disease with etidronate.

2. Rehydration in the treatment of severe hypercalcaemia.

3. Clodronate kinetics and bioavailability.

4. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity.

5. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

6. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

7. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

8. Hypercalcaemia--a hospital survey.

9. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.

10. Parenteral diphosphonates for treating malignant hypercalcemia.

Review 1. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

2. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Review 3. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Review 4. Medical management of hypercalcaemia.

5. The effect of two different doses of oral clodronate on pain in patients with bone metastases.

6. Calcium free hemodialysis: an effective therapy in hypercalcemic crisis--report of 4 cases.

7. [Calcitonin.].

8. Mechanism of malignant hypercalcaemia in carcinoma of the breast.

9. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

Review 10. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.